These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Targeting the immune microenvironment for ovarian cancer therapy. Blanc-Durand F; Clemence Wei Xian L; Tan DSP Front Immunol; 2023; 14():1328651. PubMed ID: 38164130 [TBL] [Abstract][Full Text] [Related]
27. Cellular therapy for ovarian cancer: experimental and clinical perspectives. Ingersoll SB; Ahmad S; Finkler NJ; Edwards JR; Holloway RW Curr Med Chem; 2012; 19(22):3787-93. PubMed ID: 22680925 [TBL] [Abstract][Full Text] [Related]
28. Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed. Hu X; Bian C; Zhao X; Yi T Front Immunol; 2022; 13():1034903. PubMed ID: 36275669 [TBL] [Abstract][Full Text] [Related]
33. Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer. Cheng H; Ma R; Wang S; Wang Y; Li Y; Tang Z; Dou S; Wang Y; Zhu H; Ye X; Zhang T; Zhang Y; Li S; Zhao Y; Li Y; Cui H; Chang X Front Immunol; 2021; 12():707468. PubMed ID: 34408750 [TBL] [Abstract][Full Text] [Related]
35. CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. Zhang XW; Wu YS; Xu TM; Cui MH Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979400 [TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Freedman RS; Platsoucas CD Cancer Treat Res; 1996; 82():115-46. PubMed ID: 8849947 [TBL] [Abstract][Full Text] [Related]
37. Ovarian Cancer Immunotherapy: Turning up the Heat. Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030 [TBL] [Abstract][Full Text] [Related]
38. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659 [TBL] [Abstract][Full Text] [Related]
39. Minireview: Regulatory T Cells and Ovarian Cancer. Singh M; Loftus T; Webb E; Benencia F Immunol Invest; 2016 Nov; 45(8):712-720. PubMed ID: 27420920 [TBL] [Abstract][Full Text] [Related]
40. Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models. Perales-Puchalt A; Wojtak K; Duperret EK; Yang X; Slager AM; Yan J; Muthumani K; Montaner LJ; Weiner DB Mol Ther; 2019 Feb; 27(2):314-325. PubMed ID: 30554854 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]